Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Clinical Trial to Evaluate the Effects of Broc Shot Capsules on Skin Appearance and Comfort in Adults With Reactive, Blemish-Prone, or Hormonally Affected Skin

12 novembre 2026 mis à jour par: BrocShot Inc

This is a randomized, double-blind, placebo-controlled, fully decentralized (remote) clinical trial evaluating the effects of Broc Shot Capsules on skin appearance and comfort in adults with reactive, blemish-prone, or hormonally affected skin. Fifty participants aged 18-65 years will be randomly assigned in a 1:1 ratio to receive either Broc Shot Capsules (active) or matched placebo capsules for 8 weeks.

Participants will take 2 capsules once daily and complete self-reported questionnaires and standardized self-captured skin photographs at Baseline, Week 4, and Week 8 via a secure online study platform. Expert dermatologist grading of photographs will be conducted remotely at each timepoint. The study is designed to substantiate consumer product claims related to visible skin improvement and participant-reported skin comfort, and is not intended to evaluate treatment of any clinical dermatological disease.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

50

Phase

  • N'est pas applicable

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Lieux d'étude

    • Nevada
      • Las Vegas, Nevada, États-Unis, 89101
        • Citruslabs

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

18 ans à 65 ans (Adulte, Adulte plus âgé)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Adults aged 18 to 65 years (inclusive) at the time of consent.
  • Self-reported skin concerns matching at least one of the following descriptions: I have red, itchy skin patches
  • I have dry, flaky/scaley skin patches
  • my skin has blemishes such as pimples, discoloured papules (small, tender bumps that are pink/red/purple/or darker than your natural skin tone) or pustules (a distinct white or yellow pus-filled center surrounded by a red base).
  • Generally healthy adults who are willing and able to follow the study protocol for the full 8-week duration, including taking 2 capsules of the study product once daily for 8 consecutive weeks without skipping days, answering questionnaires at Baseline, Week 4, and Week 8, and following the photograph submission protocol at Baseline, Week 4, and Week 8.
  • Willing to avoid initiating any new topical or oral skincare products, prescription medications targeting skin, or other dietary supplements specifically marketed for skin benefit during the study period.
  • Participants currently using such products who have been using them consistently for at least 3 months prior to enrollment and are willing to continue unchanged throughout the study are eligible.
  • Willing to maintain their current diet, lifestyle, sleep pattern, sun exposure habits, and skincare routine for the duration of the trial.
  • Resides within the United States.
  • Access to a smartphone or computer with internet connection and the ability to use the Citruslabs digital study platform.

Exclusion Criteria:

  • Known allergy, hypersensitivity, or intolerance to broccoli, horseradish, other cruciferous vegetables (Brassicaceae family), or any component of the study product or placebo capsule.
  • Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Currently taking prescription anticoagulant medications (e.g., warfarin, apixaban, rivaroxaban) due to the potential for product ingredients to interact with anticoagulant activity.
  • History of a severe or unstable medical condition that, in the opinion of the study team, would prevent safe participation or adherence to the protocol, including active cancer treatment.
  • Currently using any oral, topical, or biologic prescription medication specifically indicated for a diagnosed dermatological condition, unless the regimen has been stable for at least 3 months and no changes are planned during the study period.
  • Planned dermatological procedures during the study period (e.g., chemical peels, laser treatments, microneedling, injectable cosmetic procedures) that could confound skin appearance assessments.
  • Currently enrolled in another clinical or consumer research study, or plans to enroll in any such study during the 8-week study period.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Double

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Comparateur placebo: Comparateur placebo

Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

Expérimental: BrocShot Collagen

Participants will take 2 capsules once daily, with their first meal of the day, avoiding administration with hot or acidic liquids.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Clinician-Assessed Change in Overall Skin Appearance
Délai: Baseline to Week 8

Change from Baseline in overall skin appearance graded by a qualified dermatologist reviewing participant-submitted digital photographs using a binary Yes/No improvement scale assessing overall skin health, pigmentation, dryness, brightness, scarring, blemishes, redness, and flaking

Baseline to Week 8

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Participant-Reported Change in Skin Appearance
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin appearance assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Clarity
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin clarity assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Calmness
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin calmness assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Visible Skin Concerns
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported visible skin concerns assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Texture
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin texture assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Luminosity
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin luminosity assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Age Appearance
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin age appearance assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Itching and Irritation
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported itching and irritation assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Comfort
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin comfort assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8
Participant-Reported Change in Skin Confidence
Délai: Baseline, Week 4, and Week 8

Change from Baseline in self-reported skin confidence assessed via a participant-reported skin questionnaire

Baseline, Week 4, and Week 8

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

1 novembre 2026

Achèvement primaire (Estimé)

1 janvier 2027

Achèvement de l'étude (Estimé)

1 janvier 2027

Dates d'inscription aux études

Première soumission

12 novembre 2026

Première soumission répondant aux critères de contrôle qualité

12 novembre 2026

Première publication (Réel)

18 novembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

18 novembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

12 novembre 2026

Dernière vérification

1 novembre 2026

Plus d'information

Termes liés à cette étude

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Non

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner